Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.

Vikas Gupta,Srdan Verstovsek,Ruben A. Mesa,Jason Gotlib,John F. DiPersio,John Catalano,Michael W. Deininger,Carole B. Miller,Richard T. Silver,Moshe Talpaz,Elliott F. Winton,Jimmie H. Harvey,Murat O. Arcasoy,Elizabeth O. Hexner,Roger M. Lyons,Ronald Paquette,Azra Raza,Deanna Kornacki,Kang Sun,Hagop M. Kantarjian,Comfort-I investigators

Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.

2016

7012Background: The JAK1/JAK2 inhibitor RUX has demonstrated rapid and durable improvements in splenomegaly and symptoms and improved survival in the phase 3 COMFORT studies in pts with MF. Here we...

Keywords:

Physical therapy
Ruxolitinib
Myelofibrosis
Medicine
improved survival
Internal medicine
Oncology
in patient
long term outcomes

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations